D
BioCryst Pharmaceuticals, Inc. BCRX
$7.33 -$0.10-1.35%
Recommendation
Sell
Prev Close
$7.43
Volume
3,074,275
Avg Vol (90D)
2,785,713
Market Cap
$1.55B
Dividend & Yield
--
52-Week Range
$4.03 - $9.50
P/E (TTM)
--
EPS (TTM)
-$0.4301
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
BioCryst Pharmaceuticals Inc (BCRX) to Present at 24th Annual Needham Virtual Healthcare Conference
4/2/2025 - GuruFocus
BioCryst to Present at Upcoming Investor Conference
4/2/2025 - Globe Newswire
BioCryst Pharmaceuticals (BCRX, $7.25) Stochastic Oscillator left the oversold zone on April 01, 2025
4/2/2025 - Tickeron - Technical Analysis
BioCryst Pharmaceuticals (BCRX, $7.25) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 1, 2025
4/2/2025 - Tickeron - Technical Analysis
Knott David M Jr Acquires 58,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
4/2/2025 - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update
4/2/2025 - MarketBeat
Knott David M Jr Acquires 58,000 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
4/1/2025 - Ticker Report
BioCryst Pharmaceuticals (BCRX, $7.5) entered Downtrend as Momentum indicator drops below 0 level on Mar 31, 2025
4/1/2025 - Tickeron - Technical Analysis
BCRX Crosses Below Key Moving Average Level
3/31/2025 - Market News Video
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Prudential Financial Inc.
3/31/2025 - MarketBeat
Prudential Financial Inc. Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
3/30/2025 - Ticker Report
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Segall Bryant & Hamill LLC
3/27/2025 - Ticker Report
BioCryst Pharmaceuticals (BCRX, $8.05) Stochastic Oscillator left the overbought zone on March 24, 2025
3/25/2025 - Tickeron - Stocks
BioCryst Pharmaceuticals (BCRX, $8.05) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 24, 2025
3/25/2025 - Tickeron - Stocks
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 3.7% - Here's What Happened
3/22/2025 - MarketBeat
Charles Schwab Investment Management Inc. Has $14.89 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
3/21/2025 - MarketBeat
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295%
3/18/2025 - Simply Wall St
Analysts Anticipate GSSC To Hit $85
3/18/2025 - ETF Channel
BioCryst Pharmaceuticals (BCRX, $7.74) Stochastic Oscillator left the oversold zone on March 17, 2025
3/18/2025 - Tickeron - Technical Analysis
Connor Clark & Lunn Investment Management Ltd. Sells 48,460 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
3/17/2025 - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Jupiter Asset Management Ltd.
3/14/2025 - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Brokerages
3/14/2025 - MarketBeat
BioCryst Pharmaceuticals (BCRX, $7.54) RSI Indicator left the oversold zone on March 11, 2025
3/12/2025 - Tickeron - Technical Analysis
BioCryst Pharmaceuticals (BCRX, $7.38) RSI Indicator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
BioCryst Pharmaceuticals (BCRX, $7.38) RSI Indicator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$450.71M
EBITDA (TTM)
$469.00K
EBIT (TTM)
-$2.54M
Net Income (TTM)
-$88.88M
Balance Sheet
Total Assets (Q)
$490.42M
Total Debt (Q)
$841.42M
Total Liabilities (Q)
$966.35M
Book Value Per Share (Q)
-$2.28
Cash Flow
Cash from Operations (TTM)
-$52.02M
Cash from Investing (TTM)
$52.59M
Cash from Financing (TTM)
-$5.76M
Net Change in Cash (TTM)
-$6.12M
Filings
Filing Date
Tuesday, February 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.35
7-Day Total Return
-9.17%
30-Day Total Return
-21.94%
60-Day Total Return
-6.39%
90-Day Total Return
0.41%
Year to Date Total Return
-6.39%
1-Year Total Return
54.97%
2-Year Total Return
-12.43%
3-Year Total Return
-56.27%
5-Year Total Return
275.90%
52-week Low
Apr 25, 2024 - $4.03
52-week High
Feb 20, 2025 - $9.50
Valuation
Market Cap
$1.55B - Small Cap
Enterprise Value
$2.07B
Price/Sales (TTM)
3.42
Price/Book (Q)
-3.26
Dividends and Shares
Shares Outstanding
207.38M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.biocryst.com
Phone Number
919 859 1302
Address
4505 Emperor Boulevard
Durham, NC 27703
Country
United States
Year Founded
1986
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an... more
NASDAQ 04/03/2025 4:00PM Eastern Quotes delayed
Weiss Ratings